NCT07152340View on ClinicalTrials.gov

The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

May 1, 2030

Conditions

Thyroid Associated Ophthalmopathies

Interventions

DRUG

IBI311

IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.

DRUG

Glucocorticoids

500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.

Trial Locations (2)

200003

RECRUITING

Shanghai Changzheng Hospital, Changhua

NOT_YET_RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Changzheng Hospital

OTHER